The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence
Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …
death in the US. Further, in some nations, cancer has overtaken heart disease as the …
Acquired resistance to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline–Update 2022
ML Gauci, C Aristei, JC Becker, A Blom… - European Journal of …, 2022 - Elsevier
Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all
cutaneous malignancies. It is found predominantly in white populations and risk factors …
cutaneous malignancies. It is found predominantly in white populations and risk factors …
Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review
Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …
Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven
by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed …
by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed …
Non-melanoma skin cancers: Biological and clinical features
M Cives, F Mannavola, L Lospalluti, MC Sergi… - International Journal of …, 2020 - mdpi.com
Non-melanoma skin cancers (NMSCs) include basal cell carcinoma (BCC), squamous cell
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …